Regentys

REGENTYS™ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders. Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis. We are a development stage regenerative medicine company whose mission is to develop novel applications of extracellular matrix to treat IBD and put patients suffering with the disease into deep remission. Our first product, ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis. The McGowan Institute is the most ambitious regenerative program in the nation, coupling biology, clinical science and engineering. To provide patients suffering with IBD, and other diseases of the lower GI and urogenital tract, regenerative medicine treatments for their disease, to improve their quality of life.